ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Beyond H&E: CDX2 immunohistochemistry in tumor budding assessment of colorectal carcinoma.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesTumor budding (TB) phenomenon is recognized as one of the important adverse prognostic factors of colorectal carcinoma (CRC) and is currently assessed following to the International Tumor Budding Consensus Conference (ITBCC) recommendations on routine Hematoxylin and Eosin (H&E)-stained slides. However, TB evaluation may become difficult in cases showing inflammatory infiltrates, stromal desmoplasia, or glandular fragmentation. Immunohistochemical (IHC) markers, including caudal type homeobox 2 (CDX2), may improve the identification of isolated tumor buds in such situations. PATIENTS, MATERIALS AND
methodsThe retrospective study included 170 CRC cases selected from the archives of a single regional pathology center. TB was evaluated on both H&E-stained and CDX2-immunostained slides according to a modified ITBCC-based grading system including an additional Bd0 category for cases lacking identifiable tumor buds. Tumor buds were counted within a standardized field area. TB distribution was evaluated in the proximal, middle, and distal tumor regions.
resultsLow-grade budding lesions predominated in all evaluated tumor regions on both H&E and CDX2 assessment. Regional variation in TB distribution was observed along the invasive tumor front, supporting the presence of spatial heterogeneity in CRC. Comparative analysis of TB evaluation on H&E-stained preparations and on CDX2 immunolabeled preparations revealed the existence of differences between the two methods, especially in cases with low or intermediate budding activity. CDX2 immunostaining facilitated the identification of additional tumor buds, leading to the reclassification of a number of cases to higher budding categories (intermediary and high-grade budding lesions), especially in difficult cases, characterized by intense stromal reaction, inflammation or glandular fragmentation.
conclusionsThe present study demonstrated that IHC labeling should be considered primarily as a detection tool for accurate TB assessment, but other antibodies should be tested to increase the accuracy of tumor bud identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.